Clinical Trial Update: LRRK2 Mutation and Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 trial sponsored by GlaxoSmithKline investigating LRRK2 mutation-related Parkinson disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Snippet

Sponsor: GlaxoSmithKline | Conditions: Parkinson Disease | Phase 1 | Status: TERMINATED